

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州藥業股份有限公司

Guangzhou Pharmaceutical Company Limited

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

**FURTHER ANNOUNCEMENT IN RELATION TO THE
MAJOR ASSETS REORGANIZATION
AND
SUSPENSION OF TRADING**

References are made to the announcements of Guangzhou Pharmaceutical Company Limited (the “**Company**”) dated 27 March 2012, 18 June 2012, 24 August 2012, 17 September 2012, 19 September 2012 and 16 October 2012 respectively and the circular of the Company dated 4 September 2012 (the “**Circular**”) in relation to the Major Assets Reorganization. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

As notified by CSRC, the Merger and Reorganization Audit Committee of Listed Companies of CSRC will consider to approve the Major Assets Reorganization recently.

Since the Company is pending for the approval results, which is considered by the Company to be price sensitive in nature, the Company has requested for the suspension of trading in the H shares of the Company with effect from 23 November 2012 at 9:00 a.m., pending for the release of the announcement in relation to the approval results. The Company will announce the approval results of the Major Assets Reorganization on a timely basis.

The suspension of trading in the A shares of the Company is also effected on the same day.

The Board of
Guangzhou Pharmaceutical Company Limited

Guangzhou, the PRC, 23 November 2012

As at the date of this announcement, the Board comprises Mr. Yang Rongming, Mr. Li Chuyuan, Ms. Cheng Ning and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.